Kiniksa Pharmaceuticals International, plc
KNSA
Jodie situation report
Kiniksa Pharmaceuticals International, plc's current read is isolated; its market group is not confirming.
The latest filing evidence is available. 0 of 9 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
- Revenue increased 55.5% versus the comparable filing period.
- KNSA's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if KNSA's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind KNSA
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
REGNRegeneron Pharmaceuticals, Inc.supplierApr 28, 2026 ▾
“Pursuant to the Regeneron Agreement, we have entered into a supply agreement with Regeneron to purchase both clinical and commercial product.”
REGNRegeneron Pharmaceuticals, Inc.partnerApr 28, 2026 ▾
“ales and distribution of ARCALYST in all approved indications in the United States, and evenly split profits on sales, as well as third party proceeds, with Regeneron.”
Depended on by
REGNRegeneron Pharmaceuticals, Inc.partnerApr 29, 2026 ▾
“Not included in this line item are net product sales of ARCALYST, which are recorded by Kiniksa.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 1 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
KNSA is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.